DOP44: Cancer risk in a high-incidence Inflammatory Bowel Disease population – a Faroese IBD cohort studyECCO'20 Vienna 2020
1
DOP45: Increased prevalence but not incidence of myocardial infarction and stroke in patients with Inflammatory Bowel Diseases in Quebec in 1996-2015ECCO'20 Vienna 2020
1
DOP47: The changing pattern of Inflammatory Bowel Disease incidence in Northern France: A continuing increase in the young women (1988-2014)ECCO'20 Vienna 2020
1
DOP48: Gene expression landscape of epithelial monolayer in Inflammatory Bowel DiseaseECCO'20 Vienna 2020
1
DOP49: Quantitative proteomics analysis of macrophages from Crohn’s Disease patients and infected with adherent-invasive Escherichia coliECCO'20 Vienna 2020
1
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel DiseasesECCO'20 Vienna 2020
1
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesisECCO'20 Vienna 2020
1
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control studyECCO'20 Vienna 2020
1
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort studyECCO'20 Vienna 2020
1
DOP59: Maintenance of remission with tofacitinib in patients with Ulcerative Colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE OpenECCO'20 Vienna 2020
1
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)ECCO'20 Vienna 2020
1
DOP62: Morbidity after primary ileocecal resection for Crohn’s Disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centreECCO'20 Vienna 2020
1
DOP63: Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with Inflammatory Bowel Disease: A randomized controlled trialECCO'20 Vienna 2020
1